ID

6181

Beschrijving

ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00952588

Link

http://clinicaltrials.gov/ct2/show/record/NCT00952588

Trefwoorden

Versies (4)
  1. 14-11-11 14-11-11 -
  2. 06-12-13 06-12-13 - Martin Dugas
  3. 11-04-14 11-04-14 - Julian Varghese
  4. 16-12-14 16-12-14 - Martin Dugas
Geüploaded op

16 december 2014

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility AZD1152 and LDAC in AML

Engels

Eligibility AZD1152 and LDAC in AML

1 Formulieren  
Inclusion criteria
Beschrijving

Inclusion criteria

Alias
UMLS CUI-1
C1512693
Provision of written informed consent
Beschrijving

consent

Datatype

boolean

Alias
UMLS CUI-1
C0021430
Newly diagnosed male or female patients aged 60 and over
Beschrijving

Newly diagnosed patients aged 60 and over

Datatype

boolean

Alias
UMLS CUI-1
C0001779
De Novo or Secondary AML
Beschrijving

De Novo or Secondary AML

Datatype

boolean

Alias
UMLS CUI-1
C0023467
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
Beschrijving

Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia

Datatype

boolean

Alias
UMLS CUI-1
C3242266
UMLS CUI-2
C0600558
Exclusion criteria
Beschrijving

Exclusion criteria

Alias
UMLS CUI-1
C0680251
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
Beschrijving

Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product

Datatype

boolean

Alias
UMLS CUI-1
C2348568
Administration of LDAC is clinically contraindicated
Beschrijving

Administration of LDAC is clinically contraindicated

Datatype

boolean

Alias
UMLS CUI-1
C1301624
UMLS CUI-2
C0010711
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
Beschrijving

Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)

Datatype

boolean

Alias
UMLS CUI-1
C0023487
Patients with blast crisis of chronic myeloid leukaemia
Beschrijving

Patients with blast crisis of chronic myeloid leukaemia

Datatype

boolean

Alias
UMLS CUI-1
C0023473
UMLS CUI-2
C0005699
Terug naar het begin van de pagina

Similar models

Eligibility AZD1152 and LDAC in AML

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
Inclusion criteria
C1512693 (UMLS CUI-1)
consent
Item
Provision of written informed consent
boolean
C0021430 (UMLS CUI-1)
Age
Item
Newly diagnosed male or female patients aged 60 and over
boolean
C0001779 (UMLS CUI-1)
AML
Item
De Novo or Secondary AML
boolean
C0023467 (UMLS CUI-1)
Patient not eligible for Induction therapy
Item
Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following: Age >=75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia
boolean
C3242266 (UMLS CUI-1)
C0600558 (UMLS CUI-2)
Item Group
Exclusion criteria
C0680251 (UMLS CUI-1)
other trial
Item
Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
boolean
C2348568 (UMLS CUI-1)
Contraindication LDAC
Item
Administration of LDAC is clinically contraindicated
boolean
C1301624 (UMLS CUI-1)
C0010711 (UMLS CUI-2)
AML M3 APL
Item
Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
boolean
C0023487 (UMLS CUI-1)
CML blast crisis
Item
Patients with blast crisis of chronic myeloid leukaemia
boolean
C0023473 (UMLS CUI-1)
C0005699 (UMLS CUI-2)
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial